Skip to main content

UK's BBSRC Issues Call for Nearly $10M in Bioinformatics Grants

Premium

The UK's Biotechnology and Biological Sciences Research Council has issued a call for the latest round of funding under its Bioinformatics and Biological Resources Fund.

The budget for the call is "in the region" of £6 million ($9.6 million), "subject to the quality of applications received," BBSRC said. Projects will be funded for a period of five years.

Application outlines are due May 8 and full applications are due Oct. 3.

The call marks the sixth round of funding under the BBR program, which was established in 2006 to provide "proper support for resources such as databases, genetic resources and culture collections which require long term maintenance and curation," the funding agency said.

Applicants can apply for funding for a range of applications, including the establishment of a new resource "that would be applicable to a broad BBSRC user community;" the development of a "project-based resource into a community-based one;" development and maintenance of an existing community resource "to increase its relevance to a broad BBSRC user group;" and integrating existing resources.

Renewals for awards previously supported under the BBR Fund "will be assessed in competition with all other proposals submitted to the call," BBSRC said.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.